Google
NCEL 株価分析 — NEWCELX LTD. (Healthcare >> Biotechnology)
NCEL に関するよくある質問
NCELのPER（株価収益率）は？
NEWCELX LTD.（NCEL）は現在PER 4.11倍で取引されています。
NCELのROE（自己資本利益率）は？
NEWCELX LTD.のROEは1.99%です。
NCELの配当利回りは？
NEWCELX LTD.の配当利回りは0.00%です。
NCELの品質スコア（Quality Score）は？
当社のAIはNCELの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
NCELは今が買い時ですか？
当社AIのタイミングスコアは100点中55点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
NCELはどのセクターに属しますか？
NEWCELX LTD.はHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
NCEL AI Analysis Summary
Our AI summary for NCEL: NEWCELX LTD. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 4.11, ROE of 1.99%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 3.49
Price
0.13
(3.83%)
Day Change
|
|
|---|
NCEL, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.49 |
| PBV / Sector |
2.50 / 5.20
|
| Earning Per Share | 0.03 |
| PE / Sector |
4.11 / 19.97
GREAT
|
| PEG or PE/Growth / Sector |
0.08 / 1.22
GREAT
|
| Average 1M Daily Value |
0.11 M
GREAT
|
| Average 1W Daily Value |
0.03 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:13 |
| Symbol | NCEL |
| Name | NEWCELX LTD. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 5.38 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 18.10 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Hohstrasse 1, Kloten, Switzerland, 8302
Phone: 41 44 512 21 50
Website: https://newcelx.com
Sector: Healthcare >> Biotechnology
Description: NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
